Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Antioxidant and anti-inflammatory response to curcumin supplementation in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial

2021; Elsevier BV; Volume: 44; Linguagem: Inglês

10.1016/j.clnesp.2021.06.006

2405-4577

Hellen Christina Neves Rodrigues, Tatiane Fagundes Pereira Martins, Nayara Cristina Freitas e Silva Santana, Clarice Carneiro Braga, Marina Alves Coelho Silva, Luíz Carlos da Cunha, Clara Sandra de Araújo Sugizaki, Ana Tereza Vaz de Souza Freitas, Nara Aline Costa, Maria do Rosário Gondim Peixoto,

Advancements in Transdermal Drug Delivery

Summary Background and objectives Hemodialysis (HD) patients are vulnerable to malnutrition and cardiovascular complications due to many factors, including oxidative stress and inflammation. Curcumin supplementation is associated with attenuation of proinflammatory cytokines and increased activity of antioxidant enzymes, but its effects in HD patients are unknown. This study aimed to evaluate the effect of curcumin supplementation on oxidative stress and inflammation in HD patients. Methods This randomized, double-blind, placebo-controlled trial enrolled 43 HD patients and divided them into two groups: supplemented with curcumin (1 g/day) or placebo (corn starch) for 12 weeks. Demographic information and blood samples were taken at the start and the end of the study to determine serum malondialdehyde (MDA) concentrations, antioxidant enzyme activity, and high-sensitivity C-reactive protein (hs-CRP). Results The curcumin group showed a significant increase in catalase activity [Δ = 1.13 ± 2.87 versus Δ = −1.08 ± 2.68; p = 0.048] and preserved glutathione peroxidase activity [Δ = −4.23 ± 11.50 versus Δ = −14.44 ± 13.96; p < 0.01] compared with the placebo group. However, no significant changes were found in MDA concentrations, glutathione reductase activity, and hs-CRP concentrations after the intervention. Conclusion Curcumin supplementation for 12 weeks had potential effects on antioxidant response, but it was not enough to reduce oxidative stress markers and inflammation in HD patients. This trial was registered at EnsaiosClínicos.gov.br under registration number RBR-2t5zpd.